The Medical Letter on Drugs and Therapeutics
				
			FROM
ISSUE 1535
    
   			ISSUE 1535
December 4, 2017
                			
                		 Issue 1535
                		- Shingrix - An Adjuvanted, Recombinant Herpes Zoster Vaccine
 - Naldemedine (Symproic) for Opioid-Induced Constipation
 - Extended-Release Amantadine (Gocovri) for Dyskinesia in Parkinson's Disease
 - PARP Inhibitors for Ovarian Cancer
 - In Brief:  New Hypertension Guidelines
 - Three More Immune Checkpoint Inhibitors for Advanced Bladder Cancer (online only)
 
					Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
				
				Shingrix - An Adjuvanted, Recombinant Herpes Zoster Vaccine
December 4, 2017 (Issue: 1535)
				The FDA has approved an adjuvanted, recombinant
varicella zoster virus (VZV) vaccine (Shingrix – GSK)
for prevention of herpes zoster (shingles) in adults ≥50
years old. Shingrix is the second herpes zoster vaccine
to be approved in the US;...more
        			
        			
					
					
				
        			
				The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
				